Drug development


Deloitte found that the average cost of developing a new drug among the top 20 global biopharmas it studied rose 15% ($298 million) last year, to approximately $2.3 billion. That figure includes the average cost of developing a candidate from discovery through clinical trials to the market.

Many biopharmaceutical companies are using AI to speed up drug development. For example, machine-learning models are trained using information about the protein or amino-acid sequence or 3D structure of previous drug candidates, and about properties of interest.

Comments

Popular posts from this blog

Hamza Chaudhry

When their AI chums have Bob's data

Supporting Artistes (SAs)